# GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

> **NCT06851247** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 47 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Anlotinib
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **RADIATION:** radiation

## Key facts

- **NCT ID:** NCT06851247
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-03
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06851247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06851247, "GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06851247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*